Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenetic Biosciences (XBIO) Long-Term Deferred Tax (2024 - 2025)

Xenetic Biosciences' Long-Term Deferred Tax history spans 2 years, with the latest figure at $39.8 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax fell 3.25% year-over-year to $39.8 million; the TTM value through Dec 2025 reached $39.8 million, down 3.25%, while the annual FY2025 figure was $39.8 million, 3.25% down from the prior year.
  • Long-Term Deferred Tax reached $39.8 million in Q4 2025 per XBIO's latest filing, down from $41.1 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $41.1 million in Q4 2024 to a low of $39.8 million in Q4 2025.